Introduction
============

Osteogenesis imperfecta (OI) (types MIM 166200, 166210, 259420 and 166220), or brittle bone disease, is a rare connective tissue disorder characterized by increased bone fragility, low bone mass, short stature and other connective tissue manifestations. Extra-skeletal features manifest to a variable degree, including muscle weakness, brittle teeth, bluish-gray sclera and hearing defects. The traditional classification is based on clinical manifestations and radiographic criteria. The hereditary patterns of OI were classified into four primary types (I--IV) with either autosomal-dominant or ~autosomal~-recessive patterns of inheritance, exhibiting variable levels of clinical severity ([@b1-mmr-17-03-4433]). Their phenotypic presentation varies from mild to lethal and the prevalence of OI is \~1/15,000 globally and 0.04% in China ([@b2-mmr-17-03-4433],[@b3-mmr-17-03-4433]), among which half of the affected individuals are OI type I or IV while type IV has a broad phenotypic range overlapping types I and III ([@b4-mmr-17-03-4433]).

Several factors have been reported to have a role in the severity of OI, including the location of the mutation on the polypeptide chain and the particular amino acid substitution ([@b5-mmr-17-03-4433]). Over 90% of patients with OI exhibit heterozygous mutations in collagen α-1(I) chain (*COL1A1*) or collagen α-2(I) chain (*COL1A2*), genes encoding two type I pro-collagen α chains, pro-α1(I) and pro-α2(I). Translated collagen α chains include N- and C-terminals and a core triple helical domain of the Gly-X-Y triplet repeat unit. The C-terminus is involved in the reorganization and assembly of type I collagen. N-terminal cleavage results in the formation of the α-1 (I) chain which is terminated by a N-telopeptide ([@b6-mmr-17-03-4433],[@b7-mmr-17-03-4433]). All N-termini adhere to the surface of the fibrils preventing further accretion and limiting fibril diameter ([@b8-mmr-17-03-4433]). Previous studies demonstrated that environmental factors also contribute to the severity of OI. Maternal smoking during pregnancy is associated with childhood bone fractures in offspring and diet is associated with the severity of OI ([@b9-mmr-17-03-4433],[@b10-mmr-17-03-4433]). *COL1A1* and *COL1A2* are \~18 kb and 38 kb long, respectively and are located in 17q21.3--17q22, 7q21.3--7q22.3, respectively, both with \>50 exons. To date, \>1,000 different *COL1A1*/*COL1A2* mutations have been identified in patients with OI ([@b11-mmr-17-03-4433]). The present study reports a Chinese patient with OI type IV disease, who carried a novel missense mutation c.281T\>A in the N-propeptide of collagen type I α chain in the *COL1A1* gene. The present study may improve the disease-causing mutation database of collagen genes to improve the diagnosis of OI type IV.

Materials and methods
=====================

### Patients

A 6-year-old boy was admitted to the Guangxi Zhuang Autonomous Region Women and Children Care Hospital in August 2014 for genetic counseling of constitutional bone disease. According to the description of proband\'s mother, this patient previously suffered three fractures in each limb. Consequently, he was diagnosed with OI type IV following careful physical examination, capturing of radiologic images and genetic diagnosis. The patient\'s pedigree chart is presented in [Fig. 1](#f1-mmr-17-03-4433){ref-type="fig"}. From January 2015-December 2016, 300 normal Han individuals (1:1 sex ratio) aged 1--60 years were recruited. All participants agreed to carry out a genetic analysis and singed written informed consent for the study approved by the Genetic and Metabolic Central Laboratory of Guangxi Zhuang Autonomous Region Women and Children Care Hospital (Nanning, China).

### Genetic analysis

A peripheral blood sample (5 ml) was obtained from the patient, patient\'s parents and brother, and 300 normal controls. Genomic DNA was extracted from peripheral blood using Lab-Aid DNA kit (Zeesan Biotech Co., Ltd., Xiamen, China). DNA concentration was determined using NanoDrop ND-2000 spectrophotometer and software (NanoDrop 2000; NanoDrop Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Polymerase chain reaction (PCR) primers were designed using an online tool Primer version 3 ([frodo.wi.mit.edu](frodo.wi.mit.edu)) to include all exons and exon-intron boundaries of *COL1A1* and *COL1A2* genes ([Tables II](#tII-mmr-17-03-4433){ref-type="table"} and [III](#tIII-mmr-17-03-4433){ref-type="table"}). Polymerase chain reaction was conducted in a 50 µl reaction volume consisting of: 10X buffer, 1.5 mmol/l magnesium chloride, 200 µmol/l dNTPs, 400 nmol/l of each primer, 200 ng/µl DNA and 2 U Taq DNA polymerase (Takara Biotechnology Co., Ltd., Dalian, China). Initial denaturation occurred for 5 min at 95°C, followed by 30 cycles of 30 sec at 95°C, 30 sec at 60°C and 60 sec at 72°C. Final extension occurred for 7 min at 72°C. PCR products were stained with ethidium bromide and visualized on a UV transilluminator following 1.5% agarose gel electrophoresis and were sequenced directly in an ABI 3130 genetic analyzer (Thermo Fisher Scientific, Inc.). When a potential novel mutation was considered following alignment of the patient\'s genome sequence against the ClinVar ([www.ncbi.nlm.nih.gov](www.ncbi.nlm.nih.gov)), HGMD ([www.hgmd.cf.ac.uk/ac/](www.hgmd.cf.ac.uk/ac/)), HPSD (liweilab.genetics.ac.cn/HPSD/), the SNP ([www.ncbi.nlm.nih.gov/SNP](www.ncbi.nlm.nih.gov/SNP)) databases and osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases ([@b11-mmr-17-03-4433]), direct sequencing of the amplified PCR products from the same region of the 300 unaffected patients was performed to verify the possibility of the difference being caused by a polymorphism. Sorting Intolerant From Intolerant ([@b12-mmr-17-03-4433]), PolyPhen 2.0 ([@b13-mmr-17-03-4433]) and Mutation Taster ([@b14-mmr-17-03-4433]) tools were used to evaluate the pathology of the novel mutations. Three-dimensional structures of wild type (WT) and mutant COL1A1 were predicted using I-TASSER ([@b15-mmr-17-03-4433]) by importing WT and mutant COL1A1 amino acid sequences. Subsequently, DNAMAN version 8.0 was used to perform multiple sequence alignment of novel mutations of OCA2 protein from different species.

Results
=======

### Patient description

The patient diagnosed with OI was a 6-year-old boy of Han ethnicity from the Guangxi province in China. The proband began walking at the age of 16 months and suffered three bone fractures. The first fracture occurred in the right tibia/fibula following a minor injury at 2 years of age. Subsequently, there have been two fractures, each caused by either a fall or collision. Physical examination revealed short stature. The boy was 98 cm tall and weighed 16 kg, with distinct signs of dentinogenesis imperfecta, genu varum, deformities of mild scoliokyphosis and joint hypermobility. X-ray analysis demonstrated hip joint femoral head fractures, osteoporosis and multiple fractures of four limbs ([Fig. 2](#f2-mmr-17-03-4433){ref-type="fig"}). Biochemical examination demonstrated that his calcium level (2.5 mmol/l) was within normal range (2.25--2.75 mmol/l), whereas the level of serum phosphorus (0.67 mmol/l) was lower than normal serum phosphorus range (1.29--1.94 mmol/l).

### Mutation analysis

Sequence analysis revealed no functional mutations in *COL1A2* from the patient. However, a heterozygous mutation, c.281T\>A (p.Val94Asp), was identified during sequence analysis of the *COL1A1* gene. This mutation was not identified in any other family members (brother, father and mother of the proband) or ethnically matched controls ([Fig. 3](#f3-mmr-17-03-4433){ref-type="fig"}). Notably, comparison with the osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases, the Human Gene Mutation Database, HPSD and the SNP databases revealed that the mutation had not been previously identified. Functional predictions revealed that the novel missense variant may demonstrate deleterious effects by markedly altering the structure of the COL1A1 protein. Multiple sequence alignments revealed that sequence conservation at residue 94 of pro-α1(I) was poor in different organisms ([Fig. 4](#f4-mmr-17-03-4433){ref-type="fig"}).

Further protein structure prediction and analysis using I-TASSER revealed that the proportion of regions folding into an α-helix and a β-sheet would increase and the proportion of random coils would decrease in mutant protein compared with the wild-type protein. Domains 1227--1230, 1266--1271, 1277--1279, 1390--1392, 1395--1398 and 1389--1400 were predicted to be altered from random coils into β-sheets, domains 3--5, 9 and 20--22 were predicted to be altered from random coils into α-helices, domains 97--98 would form random coils instead of β-sheets, and domains 67--68 and 1259--1263 would fold into random coils instead of α-helices. The overall fibril shape was predicted to be altered ([Fig. 5](#f5-mmr-17-03-4433){ref-type="fig"}).

Discussion
==========

Severity of OI mutation is determined by a number of genetic factors, including location, mutation type and mutated residues. Over 1,000 different *COL1A1*/*COL1A2* mutations have been identified in patients with OI ([@b11-mmr-17-03-4433]), accounting for \~90% of OI cases in patients with OI type I--IV. Additionally, there are a number of mutations identified in genes encoding proteins that interact with type I collagen, affecting the development of bones and leading to different symptoms of OI. These genes include, cartilage-associated protein (MIM no. 605497), P3H1 (MIM no. 610339), serpin peptidase inhibitor clade F member 1 (MIM no. 613329), peptidyl-prolyl cis-trans isomerase B (MIM no. 123841); and the non-collagen associated genes, peptidyl-prolyl cis-trans isomerase FKBP10 (MIM no. 607063), pigment epithelium-derived factor (MIM 172860) and proto-oncogene Wnt-1 (MIM no. 615220) ([@b3-mmr-17-03-4433],[@b17-mmr-17-03-4433]--[@b21-mmr-17-03-4433]).

Type I collagen, encoded by *COL1A1* and *COL1A2*, consists of two pro-α1 chains and one pro-α2 chain, which interweave and form a dense structure. Each α chain contains three domains, one collagen triple helix repeat domain, one fibrillar collagen C-terminal propeptide and N-terminal propeptide. Collagens are generally extracellular structural proteins involved in formation of connective tissue structure. The sequence predominantly consists of repeats of the G-X-Y and polypeptide chains from triple helix motifs. The fibrillar C-terminal of collagen propeptide is the most conserved part of fibrillar collagens from invertebrates to vertebrates ([@b22-mmr-17-03-4433]). The C-terminal propeptide, also termed the COLFI domain, has a role in tissue growth and repair by controlling intracellular assembly of procollagen molecules and extracellular assembly of collagen fibrils ([@b23-mmr-17-03-4433]). The N-terminal propeptide is encoded by the first \~200 amino acids of collagen protein sequence and contains the von Willebrand C domain (vWFC) ([@b24-mmr-17-03-4433]). The N-terminal amino acids of the α1(I) chain has a role of a stabilizing anchor for the amino end of a type I collagen triple helix ([@b25-mmr-17-03-4433]). Furthermore, the von Willebrand C (vWFC) domain has a role in binding to and regulating other components, including bone morphogenetic proteins of the extracellular matrix during development ([@b26-mmr-17-03-4433]).

In the present study, the patient with OI type IV exhibited a thymine to adenine substitution mutation at nucleotide c.281 in the *COL1A1* gene, resulting in p.Val94Asp missense substitution. This variant was not identified in patient\'s parents, his brother, or 300 controls. The identified mutation was located in the second exon of the *COL1A1* gene which is a part of the N-terminal propeptide domain of the pro-α-1(I) collagen chain ([@b16-mmr-17-03-4433]). A previous study revealed that most N-terminal mutations are associated with OI/EDS ([@b27-mmr-17-03-4433]) and appear to alter the structure of N-anchor and conformation of the N-propeptide cleavage site, resulting in the incorporation of partially processed procollagen with uncleaved N-propeptides into fibrils ([@b25-mmr-17-03-4433]). During proteosynthesis, the N-terminal propeptide is removed from the pro-α-1(I) chain by a specific proteinase to form the α-1(I) chain terminated by N-telopeptide. In the present study, the patient did not have EDS, as the substitution identified in his genome was not localized in close proximity to the N-proteinase cleavage site; thus, its occurrence was not likely to prevent N-propeptide removal. The mutation identified in the present study was predicted to lead to an increased number of α-helices and β-sheets, disruption of integrity of the N-terminal and delayed N-propeptide removal, decreased fibril size and the phenotypic characteristics of OI. The substitution identified in the present study was also located in the vWF-c binding region (amino acid residues 38--96). The mutation was predicted to lead to delayed vWF-c binding and prevent normal regulation of components of the extracellular matrix during development. In addition to the symptoms of OI type IV, the patient also had low serum phosphorus levels (0.67 mmol/l), which may suggest an association between the vWF-c binding complex and regulation of serum phosphorus level. Further studies would be necessary to verify this hypothesis.

Similar mutations have been observed in the same region of the VWFC domain of N-terminal in the collagen type I α chain ([Table I](#tI-mmr-17-03-4433){ref-type="table"}) in the majority of OI patients with mild symptoms. There are two splicing mutations, 5 non-sense mutations, 4 frameshift mutations, 1 site variation (c.268_299-60del) and 2 missense mutations. The majority of patients with these mutations presented with the same mild symptoms of OI type I ([@b28-mmr-17-03-4433]--[@b32-mmr-17-03-4433]). The phenotypes resulting from null variants are caused by haploinsufficiency ([@b33-mmr-17-03-4433]). The other mutations causing OI changed the distinct activities of the N-propeptide of collagen I and its regulation of collagen fiber assembly and fibroblast function ([@b34-mmr-17-03-4433]). Similar symptoms to those exhibited in the patient of the present study are also caused by the p.Val94Asp substitution, but to a milder degree. Patient with OI with missense mutations c.182G\>T and c.266G\>T, were diagnosed with OI type I or OI type III and OI type III or OI type IV, respectively ([@b26-mmr-17-03-4433],[@b28-mmr-17-03-4433]). Smoking during pregnancy may affect the growth of fetus and lead to an increased risk of serious fractures in childhood ([@b9-mmr-17-03-4433]). Furthermore, a study by Mertz *et al* ([@b10-mmr-17-03-4433]) demonstrated that in heterozygous Col1a2^tm1Mcbr/J^ (G610C) mice, a low protein diet had beneficial effects on osteoblast differentiation and bone matrix mineralization and it also affected bone modeling and suppressed overall animal growth. To a certain extent, the severity of OI is affected by environmental factors ([@b10-mmr-17-03-4433]). Additionally, if the mutation occurs in a poorly conserved site, then the phenotype impact is relatively mild. The aforementioned findings of previous studies, combined with the description of the novel mutation c.281T\>A described in the present study, suggest that the splicing, frameshift, nonsense and missense mutation pattern, the affected *COL1A1* region, additional genes and possibly other environmental factors including smoking and diet may influence the severity of OI.

In conclusion, a novel missense mutation c.281T\>A, p.Val94Asp in exon 2 of *COL1A1* gene resulting in OI type IV and low serum phosphorus level was identified in a patient with sporadic OI. The novel missense mutation disrupted vWF-c binding and the integrity of the N-terminal of the collagen type I α chain. It remains to be elucidated how this substitution leads to the abnormal function of collagen I and low serum phosphorus levels. Detailed clinical features and molecular diagnostics have a role in expanding evidence of genetic and phenotypic heterogeneity and determining the phenotype-genotype associations in OI. The present study contributed to the understanding of *COL1A1* mutations in the Han Chinese population with OI type IV.

The present study was supported by the Open Project Program of the Shanghai Key Laboratory of Birth Defect (grant no. 16DZKF1014), Children\'s Hospital of Fudan University and the project of science and technology of Guangxi Zhuang Autonomous Region (grant no. 14124004-1-8).

![Pedigree chart of the family of the OI type IV patient. The black symbol indicates the patient with OI and white symbols represent unaffected individuals in the family. OI, osteogenesis imperfecta; L, left; R, right.](MMR-17-03-4433-g00){#f1-mmr-17-03-4433}

![X-ray images from the patient with osteogenesis imperfecta type IV. X-ray images demonstrate the multiple fractures present in the (A) left upper limb, (B) right upper limb and (C) lower limbs. (D) Hip joint femoral head fractures and osteoporosis.](MMR-17-03-4433-g01){#f2-mmr-17-03-4433}

![Sequence analysis of *COL1A1* exon 2. The nucleotide sequence of (A) the patient and (B) a representative normal subject. The patient exhibits a novel heterozygous T\>A mutation at nucleotide 281 in exon 2 (c.281T\>A), resulting in the substitution of valine with aspartic acid at codon 94 (p.V94D).](MMR-17-03-4433-g02){#f3-mmr-17-03-4433}

![Multispecies alignment of COL1A1 sequence. The novel mutation site (p.V94D) is indicated with a red box. The black background indicates complete sequence conservation; the white background indicates sequence variation.](MMR-17-03-4433-g03){#f4-mmr-17-03-4433}

![Three-dimensional structure estimation, indicating that in the variant protein there would be an increase in the proportion of α-helix and β-sheet regions, and that the random coil regions would be decreased in the mutant protein compared to the wild-type protein. The dimer alterations are indicated by an arrow. WT, wild-type; MUT, mutant.](MMR-17-03-4433-g04){#f5-mmr-17-03-4433}

###### 

Comparison of OI types with COL1A1 mutations.

  Location   Mutation                         Location             Outcome       OI type         (Refs.)
  ---------- -------------------------------- -------------------- ------------- --------------- -----------------------------------------------
  2          c.111_117del                     Deletion             Frameshift    OI IA           ([@b28-mmr-17-03-4433])
  2          c.141C\>A                        Substitution         Nonsense      OI IA           ([@b29-mmr-17-03-4433])
  2          c.174C\>A                        Substitution         Nonsense      unknown         ([@b11-mmr-17-03-4433])
  2          c.182G\>T                        Substitution         Missense      OI I, OI III    ([@b29-mmr-17-03-4433],[@b30-mmr-17-03-4433])
  2          c.189C\>A                        Substitution         Nonsense      unknown         ([@b11-mmr-17-03-4433])
  2          c.198_204dup                     Duplication          Frameshift    OI I            ([@b31-mmr-17-03-4433])
  2          c.199A\>T                        Substitution         Nonsense      OI I            ([@b11-mmr-17-03-4433])
  2          c.246delC                        Deletion             Frameshift    OI I            ([@b32-mmr-17-03-4433])
  2          c.266G\>T                        Substitution         Missense      OI III, OI IV   ([@b11-mmr-17-03-4433])
  2          c.266_266delGinsCGCCGTCCCGGGGA   Insertion/Deletion   Frameshift    OI I            ([@b11-mmr-17-03-4433])
  2          c.268_299-60del                  Deletion             Other Site    OI I            ([@b30-mmr-17-03-4433])
  2          c.285C\>A                        Substitution         Nonsense      OI I            ([@b11-mmr-17-03-4433])
  02i        c.299-5_313del                   Deletion             Splice site   OI I            ([@b11-mmr-17-03-4433])
  02i        c.299-1G\>C                      Substitution         Splice site   OI I            ([@b11-mmr-17-03-4433])

Adapted from the osteogenesis imperfecta and Ehlers-Danlos syndrome variant databases ([@b11-mmr-17-03-4433]). OI, osteogenesis imperfecta; COL1A1, collagen α-1(I) chain. 2, 2nd exon of COL1A1; 02i, 2nd intron of COL1A1.

###### 

PCR primers and conditions used for mutation analysis of the COL1A1 gene.

  Exon     Forward (5′-3′)           Reverse (5′-3′)           Product size (bp)   Annealing temp (°C)
  -------- ------------------------- ------------------------- ------------------- ---------------------
  1        GCTCTGATTGGCTGGGGCAC      CCCTTCCATTCCCGAGTCTCC     445                 60
  2        CTGAGGTTGGAGTTGGAAGCC     GTTTCTTGGTCGGTGGGTG       647                 60
  3--5     GGGAGCAGCATTAGCAAACCT     GCAAAAGAGCCTGATGTTAGCA    656                 58
  6--7     GTCAGTTTCTTCCATCCTCAGT    AGTCCCTGTCAACCTTCTCC      547                 62
  8--9     TGGTAAGATTGGAGAAGGTTG     TTCCTCTGAGTATCGTTCCC      437                 58
  10--12   TAGGCGGTGGTGGGGAGGCA      TGGTGGGACTCTGGGGATGTG     719                 63
  13--16   CCACATCCCCAGAGTCCCAC      ATCAGAGACGGAGAACCCAGG     808                 64
  17--20   GAGAGGCAAGGTTGGGTTTC      GTTCCTGGGGGTGTGGCA        802                 60
  21--23   TGCCACACCCCCAGGAAC        AAGAGGAAGAAGATGCCCAGG     428                 60
  24--25   GGCATCTTCTTCCTCTTTTGGC    AAGTCTCAGGTGTGTTTGTCCC    640                 60
  26--29   TCTCACTTCAGCCCCCTCAAC     GCGTCTAACCTCAATCCCTCT     727                 60
  30--32   CAGACCCCAGGAGGAAGGACC     GAGATTCAAAGCAGGCAGAGATG   796                 60
  33--35   GGAAACCCAGACACAAGCAGAAC   CCAGTCGGTGATGAAAAATGATG   718                 60
  36--38   CTGCCTCCATTACTGCTCCTCC    ACCTTTGCCGCCTTCTTTGCC     709                 62
  39--40   TGACAGCCCCTCCTATCCTC      CAAGTCCTGTGATGGTTTTTCTC   450                 60
  41--43   GGAGCCAAGGAGAACAGATTT     TCCGACACCCATCCCCAG        661                 60
  44--45   CTGGGAGTTGGGAGAGATGG      GAGGGGGAAACTGAGGCGAAG     487                 60
  46--47   CAGAGAGGGATTATGGGAGAGG    GAGGGAAGAGAGTGGGGATTAC    774                 60
  48--49   CCCCTCATCCCCTCTGCTCAT     CCAGCTCTGTCCATCACCCTT     800                 60
  50--51   TAGCGGCTCACTCTTCCCTC      GTTTGGGTTGCTTGTCTGTTTC    634                 60

PCR, polymerase chain reaction; bp, base pairs.

###### 

PCR primers and conditions used for mutation analysis of the COL1A2 gene.

  Exon     Forward (5′-3′)          Reverse (5′-3′)           Product size (bp)   Annealing temp
  -------- ------------------------ ------------------------- ------------------- ----------------
  1        GGTTTCGGCTAAGTTGGAGG     GGTGCCCTCCCATCTAACC       248                 60
  2        TCCCTGCCATACTTTTGACCT    ATGTAACTTCTTCCCTTCCAAGA   282                 60
  3        TTCCAAAATAGGCGGGGCTA     TGCCTTCCATCTCCAGAATAAA    738                 62
  4        GCTTCCAATCCTCCAGCTGA     ATTCGCTTCTTCTGCAGTGC      399                 60
  5        TCTTAGGTTTCTACAGGGCCT    GCACACAAAGACCAGTCCTG      356                 58
  6        AGTTAAGGCAGAGGAAGGGC     TGGCGTGGTAAAATGTGACA      399                 58
  7--10    CACAACAATGGCACTGCTAAG    GTTCTGTCAGGCATATTCAGCT    548                 60
  11--12   ACTTTGGAGGGAAGAAGTCAC    TGGAGGTCATGGGGAATTTCA     768                 60
  13--16   TCTGTGTGTCTGGCATAATTGA   ACCTTCCCTCTCCTTCTGTC      1,436               62
  17--19   CCAAGATGGCAGAATCAAGCA    AGGAAGGGCATGTCTGTGTG      872                 60
  20--23   AGCTTCTCTTTACCTTGACCCA   ACCTCATAGCCATTGTATCAAGT   1,236               60
  24       ACTCTTTTCACACTTCCCAGC    TCTCTTGCATCCCCTTGTCA      462                 62
  25--26   TCATCCGTGGCAGCATCATA     CCTGGGGATGCCATCTTGAA      749                 62
  27--29   ATTTGGGCTTTCGTGGGAAC     GGCTCATTCTCTCCATCAGC      895                 60
  30       TGCACTCATGTAGATACTGCCA   AGAGACTTGTTGCAGGGTCA      267                 60
  31       TAAATGCAAACCAGGGCTCG     TCCACTGGAATCGGATTGCT      364                 60
  32       TAGCCCAGCCTTCTTTGTGT     GCATGGTTGACAGCTGTTCA      561                 60
  33       CTGCAGCCCATTGTGATGTT     TAGAGGTCCCGGCTTCCTAA      742                 60
  34       ATCCAACCAGAGTGCAGTGA     GCGCAACATGGAGAGACTTT      429                 60
  35--38   AGCCCCGTGTCCATCTAAAA     CAGGCAGAAGAAGGGGCATA      1,404               63
  39       GCCTACCTCCTACTCCTTGG     GGGGACTGGTGTTCACATGA      403                 60
  40       ACCAGTGGCATGACATTGTT     TACTTAAACTGGGGAGGCGG      1,010               60
  41       TGCCAAGATGTAAACTCACCG    TGCAGAGGAGTAAACGCAAT      565                 60
  42       TGAATGACACGAGGCTCACT     ATACTTGGGCCCAGTTTTGC      562                 60
  43--46   AGCTACAACATAGGGGCTGG     CAAGAGTGAGATGGAGTTAGCC    1,136               60
  47--49   TGCACTGCTGAAATAGGTTGT    GAAATGAGGTTGGGTGCTGG      1,247               60
  50       TTTTCATGGAGGAGGGGAGG     CCCAGGAAAGGAACAGGTCT      497                 60
  51       AGATGACCTTGCCTCAGTCT     AGGCCACTGAAGTCTCAAGA      812                 60
  52       CCCTCCCACTAAAGACACCC     TGTGCAGAAGAAATGGAAGGA     434                 60

PCR, polymerase chain reaction; bp, base pairs.
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